The Supreme Court let mifepristone come through the mail again. Just for now.
It happens on Thursday. The high court extends a stay. That keeps alive a drug many rely on. Only two justices pushed back. Clarence Thomas and Samuel Alito said no.
There is a fight over Louisiana law. And virtual care. The state sued the FDA in 2025. They didn’t like the mail-order model. The FDA had opened the door during the pandemic. Louisiana argued the pills carried risk. They claimed telehealth prescriptions undercut the state’s abortion ban.
The Fifth Circuit agreed with them.
That ruling would have forced people to go to clinics in person. Two companies making the drug asked the Supreme Court for help. If the lower courts had their way, the mail stops working. Access shrinks. Geography dictates survival.
Mifepristone is old news in medicine. The FDA approved it in 2000 usually paired with misoprostol It works up to ten weeks into pregnancy. Most data says it is safe. The evidence is overwhelming.
The Trump administration wants a closer look anyway. They opened a new review. Into the safety. Into the efficacy. Some experts worry this isn’t about safety. Is it? Or is it about cherry-picking numbers? To fit a view already formed? The review might be flawed. Or worse.
The review’s findings will likely be biased from the start.
It isn’t just policy. It’s practice. A lot of women depend on this access. The law is a blunt instrument.
The clock is ticking on this specific ruling. It stands. But just for the moment.
What comes next is never certain. The rules could change overnight. Or slowly. Or not at all. 📦
